Early combined therapy for COVID-19 in immunocompromised patients: a promising approach against viral persistence and drug resistance
Abstract Immunocompromised (IC) patients face significant challenges in managing COVID-19 due to their heightened susceptibility to severe illness, persistent infections, and the potential development of drug resistance.Studies indicate that IC patients, particularly those with hematologic malignancies (HM), hematopoietic stem cell transplants (HSC